Glycemic variability diary as a tool for assessing the effectiveness of diabetes therapy. Clear and accessible. Case series

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Modern approaches to the therapy of diabetes mellitus (DM) involve the assessment of the success of therapy and glycemic control by the glycated hemoglobin level. Recently, however, the assessment of glycemic variability (GV) has become of great importance. Previously, assessment of GV required continuous monitoring of glycemia. Currently, such a tool as a of glycemic variability diary (GVD) is available.

Description of case series. Five clinical cases of patients with decompensated DM2 are presented. All patients underwent an assessment of glycemic control according to GVD before and after changing therapy. GVD that makes it possible to assess the efficacy and safety of DM therapy, and glycemic variability is used as an independent risk factor for the development of severe hypoglycemic conditions, diabetic micro- and macroangiopathy [1].

Conclusion. GVD has proven to be effective and important in the outpatient setting. The improvement of carbohydrate metabolism compensation when switching to ultra-long-acting insulin degludec with an increase in the time spent in the target glycemic range, a decrease in glycemic variability has been clearly demonstrated.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ekaterina Smirnova

City Polyclinic № 44, St. Petersburg

Хат алмасуға жауапты Автор.
Email: katrin_cat@list.ru
ORCID iD: 0000-0003-2487-0038

Endocrinologist, City Polyclinic № 44, St. Petersburg, Russia

Ресей, St. Petersburg

Әдебиет тізімі

  1. Анциферов М.Б., Демидов Н.А., Котешкова О.М. и др. Оценка вариабельности уровня гликемии на основе самоконтроля. Результаты пилотного проекта. Эндокринология: новости, мнения, обучение. 2021;10(2):26–31. [Antsiferov M.B., Demidov N.A., Koteshkova O.M. Evaluation of the variability of the level of glycemia based on self-control. Pilot project results. Endokrinologiya: novosti, mneniya, obuchenie. 2021;10(2):26–31. (In Russ.)]. doi: 10.33029/2304-9529-2021-10-2-26-31.
  2. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. doi: 10.1016/S0140-6736(98)07019-6.
  3. Battelino T., Danne T., Bergenstal R.M., et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diab Care. 2019;42(8):1593–603. doi: 10.2337/dci19-0028.
  4. Hashimoto K., Osugi T., Noguchi S., et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diab Care. 2010;33(3):509–11. doi: 10.2337/dc09-1954.
  5. Inaba M., Okuno S., Kumeda Y., et al. Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896–903. Doi: 10.1681/ ASN.2006070772.
  6. Bry L., Chen P.C., Sacks D.B. Effects of Hemoglobin Variants and Chemically Modified Derivatives on Assays for Glycohemoglobin. Clin Chem. 2001;47(2):153–63. doi: 10.1093/clinchem/47.2.153.
  7. Ford E.S., Cowie C.C., Li C., et al. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diab. 2011;3(1):67–73. doi: 10.1111/j.1753-0407.2010.00100.x.
  8. Клинические рекомендации Сахарный диабет 2 типа у взрослых, МЗ РФ, 2022.
  9. Davies M.J., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–66. doi: 10.1007/s00125- 022-05787-2.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
2. Fig. 1. An example of the unreliability of the results of the HbA1c assessment in a patient with diabetes and anemia

Жүктеу (139KB)
3. Fig. 2. Part of DVG. Information for the interpretation of the obtained indicators

Жүктеу (211KB)
4. Fig. 3. DHD Patient 1 (November 2022)

Жүктеу (255KB)
5. Fig. 4. DHD Patient 1 3 months after switching therapy (February 2023)

Жүктеу (250KB)
6. Fig. 5. DHD Patient 2 (November 2022)

Жүктеу (252KB)
7. Fig. 6. DHD Patient 2 3 months after switching therapy (February 2023)

Жүктеу (257KB)
8. Fig. 7. DHD Patient 3 (November 2022)

Жүктеу (252KB)
9. Fig. 8. DHD Patient 3 3 months after switching therapy (February 2023)

Жүктеу (254KB)
10. Fig. 9. DHD Patients 4 (November 2022)

Жүктеу (257KB)
11. Fig. 10. DHD Patient 4 3 months after switching therapy (February 2022)

Жүктеу (263KB)
12. Fig. 11. DHD Patient 5 (November 2022)

Жүктеу (256KB)
13. Fig. 12. DHD Patient 5 3 months after switching therapy (February 2023)

Жүктеу (255KB)

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>